NCT07010497 2026-03-18
IAPETUS
Asan Medical Center
Phase 2 Recruiting
Clinical Trials
466 trialsNCT05528952 2026-03-16
TERTIO
Centre Hospitalier Universitaire de Besancon
Phase 2 Recruiting
NCT01165346 2026-03-13
CKNO-HEP
Centre Oscar Lambret
Phase 2 Completed
NCT05901519 2026-03-13
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT07381634 2026-03-11
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT07463248 2026-03-11
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
West China Hospital
Phase 2 Not yet recruiting
NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT04721132 2026-03-05
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06789848 2026-02-27
Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT04945720 2026-02-25
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT04134559 2026-02-24
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07422753 2026-02-20
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT04522544 2026-02-18
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT05669339 2026-02-18
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
University of Florida
Phase 2 Recruiting
NCT06851104 2026-02-18
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
Guangxi Medical University
Phase 2 Terminated
NCT07413354 2026-02-17
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
Tongji Hospital
Phase 2 Recruiting
NCT07405086 2026-02-12
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT03519997 2026-02-11
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT05176223 2026-02-05
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
Mayo Clinic
Phase 2 Completed
NCT07380633 2026-02-02
Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06553885 2026-01-29
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05166239 2026-01-23
HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
Peking University
Phase 2 Completed
NCT04505553 2026-01-21
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase 2 Completed
NCT04550481 2026-01-21
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
Northwestern University
Phase 2 Active not recruiting
NCT07331883 2026-01-21
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Ruijin Hospital
Phase 2 Recruiting
NCT07314372 2026-01-20
FAD-HCC-001
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT07324824 2026-01-16
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT05349331 2026-01-15
WATCH
Sun Yat-sen University
Phase 2 Completed
NCT07337421 2026-01-13
Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
Northern Jiangsu People's Hospital
Phase 2 Recruiting
NCT07337460 2026-01-13
Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
Northern Jiangsu People's Hospital
Phase 2 Recruiting
NCT06526104 2026-01-06
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT03727633 2026-01-05
LIDA-BII
University Hospital, Montpellier
Phase 2 Recruiting
NCT07317414 2026-01-05
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT03199274 2026-01-02
Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer
Thomas Jefferson University
Phase 2 Completed
NCT07312292 2025-12-31
RADIANT
UMC Utrecht
Phase 2 Not yet recruiting
NCT05532319 2025-12-30
FRONT-1
Guangxi Medical University
Phase 2 Completed
NCT07285044 2025-12-22
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT04798781 2025-12-11
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Cedars-Sinai Medical Center
Phase 2 Completed
NCT07179900 2025-12-11
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT07274774 2025-12-10
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT04430452 2025-12-08
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
University of California, San Francisco
Phase 2 Recruiting
NCT06265285 2025-12-04
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Phase 2 Recruiting
NCT04204850 2025-12-03
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
University Health Network, Toronto
Phase 2 Recruiting
NCT06902246 2025-12-02
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Recruiting
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT06632717 2025-11-25
Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma
National Taiwan University Hospital
Phase 2 Recruiting
NCT07239245 2025-11-25
ATTACH
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT07246668 2025-11-24
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Yonsei University
Phase 2 Recruiting
NCT04172779 2025-11-20
ECHO-B
University of Texas Southwestern Medical Center
Phase 2 Not yet recruiting
NCT04828486 2025-11-18
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
Mayo Clinic
Phase 2 Completed